Alcon's anticipated split from Novartis has yet to be completed but the eye care business already is looking for ways to build out its portfolio for when it becomes a standalone company.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,